Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

XML

Immunotherapy biomarkers

Original research

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity

Online download statistics by month:

Online download statistics by month: June 2020 to October 2022

	Abstract	Full	Pdf
Jun 2020	577	577	328
Jul 2020	331	331	114
Aug 2020	108	106	46
Sep 2020	146	146	58
Oct 2020	105	105	51
Nov 2020	128	127	46
Dec 2020	140	140	50
Jan 2021	161	161	62
Feb 2021	118	118	44
Mar 2021	141	141	69
Apr 2021	183	183	86
May 2021	138	138	82
Jun 2021	102	102	69
Jul 2021	95	95	56
Aug 2021	83	85	47
Sep 2021	94	94	50
Oct 2021	147	148	84
Nov 2021	151	152	72
Dec 2021	155	158	65
Jan 2022	142	154	46
Feb 2022	103	105	46
Mar 2022	174	187	92
Apr 2022	202	213	80
May 2022	175	185	70
Jun 2022	230	236	57
Jul 2022	163	173	71
Aug 2022	132	137	57
Sep 2022	155	157	204
Oct 2022	150	152	66
Total	4729	4806	2268